GoodRx Holdings (GDRX) EBIT (2019 - 2026)

GoodRx Holdings (GDRX) has 8 years of EBIT data on file, last reported at $14.0 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT fell 40.08% year-over-year to $14.0 million; the trailing twelve-month figure through Mar 2026 stood at $78.1 million (down 4.55% YoY), and the FY2025 full-year result was $87.5 million, up 32.87% from the prior year.
• EBIT fell to $14.0 million in Q1 2026, from $22.7 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $26.8 million in Q2 2025 to a low of -$38.3 million in Q3 2023.
• A 5-year average of $8.4 million and a median of $14.6 million in 2025 frame the typical range for EBIT.
• Peak annual rise in EBIT reached 552.38% in 2023, while the deepest fall reached 1152.85% in 2023.
• Tracing GDRX's EBIT over 5 years: stood at $1.7 million in 2022, then sank by 1152.85% to -$18.3 million in 2023, then surged by 199.41% to $18.2 million in 2024, then grew by 24.77% to $22.7 million in 2025, then tumbled by 38.24% to $14.0 million in 2026.
• Business Quant data shows GDRX's EBIT at $14.0 million in Q1 2026, $22.7 million in Q4 2025, and $14.6 million in Q3 2025.